Drug intelligence / Profile preview

RO6799477

Development stage: Phase 1
Lead developer: Roche
Modality: Small Molecules
Administration: Oral

Overview

RO6799477 is an oral small molecule drug developed by Roche for the treatment of type 2 diabetes mellitus. It is under investigation as a therapeutic agent in endocrinology and metabolic diseases. As of the latest available information, it has been in Phase I clinical development. The precise mechanism of action has not been disclosed publicly, but it is being evaluated for its potential to address glucose regulation in type 2 diabetes.

Beyond the preview

Go deeper on RO6799477.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RO6799477.

Explore the full profile